A.N. Kuznetsov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
A.N. Kuznetsov has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- O.V. Golovanova
Pirogov Russian National Research Medical University
4 shared publications - Igor Anatolievich Zolotukhin
Pirogov Russian National Research Medical University
3 shared publications - Oksana Igorevna Efremova
Pirogov Russian National Research Medical University
3 shared publications - Aleksey Kamaev
Ryazan State Medical University
2 shared publications - Igor Aleksandrovich Suchkov
Ryazan State Medical University named after academician I.P. Pavlov, Ministry of Health of the Russian Federation
2 shared publications A.V. Andryashkin
Pirogov Russian National Research Medical University
1 shared publication
Latest Publications
- 27 September 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (3)
Onset, Time Course and Duration of Venoactive Drugs Effect on Venous Symptoms in Patients with Chronic Venous Disease
Onset and duration of effect of venoactive drug (VAD) and topical agent on venous symptoms are unclear. Objective — to determine onset and duration of the effect of treatment with VAD and/or local gel use on venous symptoms. Material and methods. 121 patients (C1—C3S) were included in the multicenter prospective study. First group patients received VAD with topical agent. Second group patients received VAD only. Third group patients received local agent only. Duration of therapy was 2 months. Leg’s discomfort related to venous symptoms, quality of life, effect onset, duration of the effect after therapy completion were assessed. The symptoms were registered at 10 visits: beginning of therapy, after one, two, four, six and weeks (end of therapy), 3, 4, 5 and 6 months after the start of therapy. Results. 88, 82 and 76% of patients reported complete symptoms resolution or significant improving in the first, second and third groups, respectively. The effect was increasing during the first month of therapy with 70—80% of patients with improvement by this time. Baseline discomfort level was a predictor of insufficient effect. The higher level was related to worse results (OR=0.97 (95% CI: 0.94—0.99), p=0.017). Gender, age, CEAP disease class, obesity did not affect the result. The use of a local agent alone was associated with a higher probability of symptom persistence (OR=2.89 (95% CI: 0.97—8.54), p=0.056). Symptoms increased and returned within 4 months after discontinuation of therapy. Complete return of symptoms occurred in 22, 16 and 38% of patients in the first, second and third groups, respectively by the end of the follow-up. Conclusions. A two-month course of VAD treatment (and/or local gel use) effectively alleviates venous symptoms. Next course should be prescribed between one and four months after completing the two-month course, depending on increasing of symptoms severity. The use of a local agent alone is less effective, the achieved result is less stable.
- 27 September 2025
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 19 (3)
Onset, Time Course and Duration of Venoactive Drugs Effect on Venous Symptoms in Patients with Chronic Venous Disease
Onset and duration of effect of venoactive drug (VAD) and topical agent on venous symptoms are unclear. Objective — to determine onset and duration of the effect of treatment with VAD and/or local gel use on venous symptoms. Material and methods. 121 patients (C1—C3S) were included in the multicenter prospective study. First group patients received VAD with topical agent. Second group patients received VAD only. Third group patients received local agent only. Duration of therapy was 2 months. Leg’s discomfort related to venous symptoms, quality of life, effect onset, duration of the effect after therapy completion were assessed. The symptoms were registered at 10 visits: beginning of therapy, after one, two, four, six and weeks (end of therapy), 3, 4, 5 and 6 months after the start of therapy. Results. 88, 82 and 76% of patients reported complete symptoms resolution or significant improving in the first, second and third groups, respectively. The effect was increasing during the first month of therapy with 70—80% of patients with improvement by this time. Baseline discomfort level was a predictor of insufficient effect. The higher level was related to worse results (OR=0.97 (95% CI: 0.94—0.99), p=0.017). Gender, age, CEAP disease class, obesity did not affect the result. The use of a local agent alone was associated with a higher probability of symptom persistence (OR=2.89 (95% CI: 0.97—8.54), p=0.056). Symptoms increased and returned within 4 months after discontinuation of therapy. Complete return of symptoms occurred in 22, 16 and 38% of patients in the first, second and third groups, respectively by the end of the follow-up. Conclusions. A two-month course of VAD treatment (and/or local gel use) effectively alleviates venous symptoms. Next course should be prescribed between one and four months after completing the two-month course, depending on increasing of symptoms severity. The use of a local agent alone is less effective, the achieved result is less stable.
- 27 December 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (4)
Efficiency of Local Therapy in Patients with Venous Symptoms
Objective. To evaluate the efficacy and of local therapy for symptoms of chronic venous diseases (CVD). Material and methods. An open observational study included patients with CVD C1S-C2S. All patients used local agents as monotherapy for 14 days. The main evaluation criteria were VAS scores of symptoms and ease of use of local agents. Results. There were 45 patients aged 28—68 years. They were divided into 3 equal groups: group 1 — topical drug based on heparin, escin and essential phospholipids; group 2 — heparin-containing gel; group 3 — gel based on troxerutin, heparin and dexpanthenol. In all groups, we observed positive changes of all symptoms and manifestations of CVD, such as pain syndrome, fatigue in legs, swelling and cramps. In the 1st group, almost all symptoms decreased by 51%. However, there were no significant differences. Effectiveness and ease of use were the highest in the same group. Conclusion. Local therapy in patients with subjective symptoms of CVD can reduce the incidence and severity of clinical manifestations. A gel based on heparin, escin and essential phospholipids may be the most preferable among topical drugs regarding the effectiveness and ease of use.
- 27 December 2024
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 18 (4)
Efficiency of Local Therapy in Patients with Venous Symptoms
Objective. To evaluate the efficacy and of local therapy for symptoms of chronic venous diseases (CVD). Material and methods. An open observational study included patients with CVD C1S-C2S. All patients used local agents as monotherapy for 14 days. The main evaluation criteria were VAS scores of symptoms and ease of use of local agents. Results. There were 45 patients aged 28—68 years. They were divided into 3 equal groups: group 1 — topical drug based on heparin, escin and essential phospholipids; group 2 — heparin-containing gel; group 3 — gel based on troxerutin, heparin and dexpanthenol. In all groups, we observed positive changes of all symptoms and manifestations of CVD, such as pain syndrome, fatigue in legs, swelling and cramps. In the 1st group, almost all symptoms decreased by 51%. However, there were no significant differences. Effectiveness and ease of use were the highest in the same group. Conclusion. Local therapy in patients with subjective symptoms of CVD can reduce the incidence and severity of clinical manifestations. A gel based on heparin, escin and essential phospholipids may be the most preferable among topical drugs regarding the effectiveness and ease of use.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Venoactive Drug Treatment or Compression Stockings in Warm Weather Season in Symptomatic Patients with Chronic Venous Disease
Adherence to compression therapy is low in many patients, especially in warm weather. Venoactive drug (VAD) therapy alone may be an option in patients with symptomatic chronic venous disease (CVD). Objective. To compare VAD therapy and compression therapy in symptomatic CVD patients during warm season. Material and methods. A comparative non-randomized study included 60 patients with CVD class C1S, C2S and C3S. Patients were recruited between May and September. VAD containing micronized diosmin 900 mg and hesperidin 100 mg one tablet per day for 90 days was prescribed in 41 patients (main group). Compression stockings were recommended in 19 patients (control group). End-points were discomfort in the lower legs related to CVD symptoms, quality of life (QoL) and venous symptoms. Results. Legs discomfort decreased from 52±22 to 32±19 (p<0.0001) after VAD therapy and from 49±21 to 42±17 (p=0.02) after compression therapy. VAD therapy resulted more significant regression of discomfort (38% and 14%, respectively, p<0.001). QoL improved from 64±16 to 78±12 (p<0.0001) after VAD treatment and from 72±14 to 77±8 (p=0.02) after compression therapy. Mean improvement was 22% and 5%, respectively (p<0.001). All venous symptoms decreased significantly after medical therapy. In the main group, 32 (78%) patients were adherent to VAD treatment, and only 5 (26.4%) patients complied with compression therapy. Conclusion. VAD therapy alone significantly reduces venous symptoms and improves QoL in warm weather. VAD treatment alone can be recommended as an alternative to compression therapy in warm season.
- 24 March 2023
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 17 (1)
Venoactive Drug Treatment or Compression Stockings in Warm Weather Season in Symptomatic Patients with Chronic Venous Disease
Adherence to compression therapy is low in many patients, especially in warm weather. Venoactive drug (VAD) therapy alone may be an option in patients with symptomatic chronic venous disease (CVD). Objective. To compare VAD therapy and compression therapy in symptomatic CVD patients during warm season. Material and methods. A comparative non-randomized study included 60 patients with CVD class C1S, C2S and C3S. Patients were recruited between May and September. VAD containing micronized diosmin 900 mg and hesperidin 100 mg one tablet per day for 90 days was prescribed in 41 patients (main group). Compression stockings were recommended in 19 patients (control group). End-points were discomfort in the lower legs related to CVD symptoms, quality of life (QoL) and venous symptoms. Results. Legs discomfort decreased from 52±22 to 32±19 (p<0.0001) after VAD therapy and from 49±21 to 42±17 (p=0.02) after compression therapy. VAD therapy resulted more significant regression of discomfort (38% and 14%, respectively, p<0.001). QoL improved from 64±16 to 78±12 (p<0.0001) after VAD treatment and from 72±14 to 77±8 (p=0.02) after compression therapy. Mean improvement was 22% and 5%, respectively (p<0.001). All venous symptoms decreased significantly after medical therapy. In the main group, 32 (78%) patients were adherent to VAD treatment, and only 5 (26.4%) patients complied with compression therapy. Conclusion. VAD therapy alone significantly reduces venous symptoms and improves QoL in warm weather. VAD treatment alone can be recommended as an alternative to compression therapy in warm season.
- 1 January 2022
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 16 (4)
Incidence and Severity of the Cord Feeling after Thermal Ablation of Great Saphenous Vein Decrease under Topical Treatment
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить частоту и выраженность симптома «струны» после термической облитерации ствола большой подкожной вены (БПВ) и возможности его купирования. МАТЕРИАЛ И МЕТОДЫ Проведено сравнительное клиническое исследование, в которое были включены 80 пациентов с варикозной болезнью нижних конечностей в системе БПВ (класс C2—C4). Всем пациентам выполняли радиочастотную облитерацию ствола БПВ на бедре. В послеоперационном периоде, наряду со стандартной терапией, назначали местное лечение: в основной группе (40 пациентов) — гель, содержащий троксерутин и индометацин, в контрольной (40 пациентов) — гель для ухода за кожей, которые пациенты наносили в проекции облитерированной БПВ в течение 10 сут. Оценивали частоту и выраженность симптома «струны» и болевого синдрома. РЕЗУЛЬТАТЫ Через 10 сут симптом «струны» выявили у 20 (50%) и 28 (70%) пациентов основной и контрольной групп соответственно (p=0,11). Выраженность симптома по визуальной аналоговой шкале составила 1,02±1,64 (от 0 до 7) и 2,04±2,31 (от 0 до 8,8) балла соответственно (p=0,017). Через 1 мес после вмешательства симптом «струны» сохранился у 7 (18%) и 18 (45%) пациентов соответственно (p=0,015). Боль в проекции облитерированной БПВ на 5-е сутки отмечали 13 (33%) больных в основной группе и 17 (43%) — в контрольной (p=0,489). Обезболивающие препараты в первые 10 сут использовали 2 (5%) и 9 (23%) пациентов соответственно (p=0,048). ЗАКЛЮЧЕНИЕ Местное применение геля с индометацином и троксерутином привело к снижению выраженности и частоты выявления симптома «струны» после радиочастотной облитерации большой подкожной вены.
- 1 January 2022
- Published by Media Sphere Publishing Group in Journal of Venous Disorders
- Vol. 16 (4)
Incidence and Severity of the Cord Feeling after Thermal Ablation of Great Saphenous Vein Decrease under Topical Treatment
ЦЕЛЬ ИССЛЕДОВАНИЯ Оценить частоту и выраженность симптома «струны» после термической облитерации ствола большой подкожной вены (БПВ) и возможности его купирования. МАТЕРИАЛ И МЕТОДЫ Проведено сравнительное клиническое исследование, в которое были включены 80 пациентов с варикозной болезнью нижних конечностей в системе БПВ (класс C2—C4). Всем пациентам выполняли радиочастотную облитерацию ствола БПВ на бедре. В послеоперационном периоде, наряду со стандартной терапией, назначали местное лечение: в основной группе (40 пациентов) — гель, содержащий троксерутин и индометацин, в контрольной (40 пациентов) — гель для ухода за кожей, которые пациенты наносили в проекции облитерированной БПВ в течение 10 сут. Оценивали частоту и выраженность симптома «струны» и болевого синдрома. РЕЗУЛЬТАТЫ Через 10 сут симптом «струны» выявили у 20 (50%) и 28 (70%) пациентов основной и контрольной групп соответственно (p=0,11). Выраженность симптома по визуальной аналоговой шкале составила 1,02±1,64 (от 0 до 7) и 2,04±2,31 (от 0 до 8,8) балла соответственно (p=0,017). Через 1 мес после вмешательства симптом «струны» сохранился у 7 (18%) и 18 (45%) пациентов соответственно (p=0,015). Боль в проекции облитерированной БПВ на 5-е сутки отмечали 13 (33%) больных в основной группе и 17 (43%) — в контрольной (p=0,489). Обезболивающие препараты в первые 10 сут использовали 2 (5%) и 9 (23%) пациентов соответственно (p=0,048). ЗАКЛЮЧЕНИЕ Местное применение геля с индометацином и троксерутином привело к снижению выраженности и частоты выявления симптома «струны» после радиочастотной облитерации большой подкожной вены.